Elevance Health, Inc. ELV
We take great care to ensure that the data presented and summarized in this overview for Elevance Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELV
View all-
Vanguard Group Inc Valley Forge, PA21.2MShares$11.5 Billion0.22% of portfolio
-
Black Rock Inc. New York, NY20.9MShares$11.4 Billion0.26% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11.7MShares$6.37 Billion0.74% of portfolio
-
State Street Corp Boston, MA10.5MShares$5.7 Billion0.25% of portfolio
-
Geode Capital Management, LLC Boston, MA4.69MShares$2.55 Billion0.23% of portfolio
-
Sanders Capital, LLC West Palm Beach, FL4.51MShares$2.45 Billion3.9% of portfolio
-
Wellington Management Group LLP Boston, MA4.5MShares$2.45 Billion0.42% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.6MShares$1.96 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA3.5MShares$1.9 Billion0.38% of portfolio
-
Alliancebernstein L.P. New York, NY3MShares$1.63 Billion0.57% of portfolio
Latest Institutional Activity in ELV
Top Purchases
Top Sells
About ELV
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Insider Transactions at ELV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Ramiro G Peru Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.93%
|
-
|
May 15
2024
|
Ryan M. Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+6.07%
|
-
|
May 15
2024
|
Deanna D Strable Soethout Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+27.08%
|
-
|
May 15
2024
|
Elizabeth E Tallett Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.63%
|
-
|
May 15
2024
|
Susan D. De Vore Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+18.57%
|
-
|
May 15
2024
|
Robert L Dixon Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.73%
|
-
|
May 15
2024
|
Lewis Hay Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+3.44%
|
-
|
May 15
2024
|
Bahija Jallal Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+8.48%
|
-
|
May 15
2024
|
Antonio F Neri Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+8.23%
|
-
|
May 15
2024
|
R Kerry Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
388
+4.12%
|
-
|
Apr 24
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Open market or private sale
|
Direct |
6,199
-9.71%
|
$3,297,868
$532.41 P/Share
|
Apr 24
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Exercise of conversion of derivative security
|
Direct |
2,043
+5.75%
|
$486,234
$238.27 P/Share
|
Apr 23
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
SELL
Open market or private sale
|
Direct |
14,111
-15.53%
|
$7,535,274
$534.23 P/Share
|
Apr 23
2024
|
Felicia F Norwood EVP & President,Gov Health Ben |
BUY
Exercise of conversion of derivative security
|
Direct |
5,473
+10.72%
|
$1,302,574
$238.27 P/Share
|
Mar 08
2024
|
Charles Morgan Kendrick Jr EVP & President, Commercial |
SELL
Open market or private sale
|
Direct |
2,432
-13.31%
|
$1,216,000
$500.46 P/Share
|
Mar 06
2024
|
Ronald W Penczek CAO & Controller |
SELL
Open market or private sale
|
Direct |
916
-34.18%
|
$461,664
$504.58 P/Share
|
Mar 04
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
SELL
Open market or private sale
|
Direct |
21,095
-20.02%
|
$10,547,500
$500.18 P/Share
|
Mar 04
2024
|
Peter D Haytaian EVP & Pres Carelon & CarelonRx |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+27.28%
|
$2,490,000
$166.97 P/Share
|
Mar 01
2024
|
Blair Williams Todt EVP, CLO & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
8,691
+22.23%
|
-
|
Mar 01
2024
|
Blair Williams Todt EVP, CLO & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,650
-30.13%
|
$1,821,350
$499.11 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 110K shares |
---|---|
Exercise of conversion of derivative security | 28K shares |
Payment of exercise price or tax liability | 34.7K shares |
---|---|
Open market or private sale | 52.4K shares |